181 related articles for article (PubMed ID: 32962435)
1. Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
Anbar HS; El-Gamal MI; Tarazi H; Lee BS; Jeon HR; Kwon D; Oh CH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1712-1726. PubMed ID: 32962435
[TBL] [Abstract][Full Text] [Related]
2. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
3. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAF
Ali EMH; Abdel-Maksoud MS; Ammar UM; Mersal KI; Ho Yoo K; Jooryeong P; Oh CH
Bioorg Chem; 2021 Jan; 106():104508. PubMed ID: 33280830
[TBL] [Abstract][Full Text] [Related]
5. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening.
Ammar UM; Abdel-Maksoud MS; Ali EMH; Mersal KI; Ho Yoo K; Oh CH
Bioorg Chem; 2020 Jul; 100():103967. PubMed ID: 32470760
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
Khan MA; El-Gamal MI; Tarazi H; Choi HS; Oh CH
Future Med Chem; 2016 Dec; 8(18):2197-2211. PubMed ID: 27845592
[TBL] [Abstract][Full Text] [Related]
8. Discovery of New Imidazo[2,1-
Abdel-Maksoud MS; El-Gamal MI; Lee BS; Gamal El-Din MM; Jeon HR; Kwon D; Ammar UM; Mersal KI; Ali EMH; Lee KT; Yoo KH; Han DK; Lee JK; Kim G; Choi HS; Kwon YJ; Lee KH; Oh CH
J Med Chem; 2021 May; 64(10):6877-6901. PubMed ID: 33999621
[TBL] [Abstract][Full Text] [Related]
9. Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies.
Mayrhofer JE; Enzler F; Feichtner A; Röck R; Fleischmann J; Raffeiner A; Tschaikner P; Ogris E; Huber RG; Hartl M; Schneider R; Troppmair J; Torres-Quesada O; Stefan E
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31105-31113. PubMed ID: 33229534
[TBL] [Abstract][Full Text] [Related]
10. Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.
Abdel-Maksoud MS; Ammar UM; Oh CH
Bioorg Med Chem; 2019 May; 27(10):2041-2051. PubMed ID: 30955995
[TBL] [Abstract][Full Text] [Related]
11. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
12. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
[TBL] [Abstract][Full Text] [Related]
13. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
15. Discovery of New Quinolone-Based Diarylamides as Potent B-RAF
Kim HJ; Park JW; Seo S; Cho KH; Alanazi MM; Bang EK; Keum G; El-Damasy AK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834628
[TBL] [Abstract][Full Text] [Related]
16. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF
Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH
Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
[TBL] [Abstract][Full Text] [Related]
19. A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma.
Babu A; Laila SP; Fernandez A
Anticancer Agents Med Chem; 2021; 21(15):2066-2074. PubMed ID: 33372883
[TBL] [Abstract][Full Text] [Related]
20. Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
Zaraei SO; Sbenati RM; Alach NN; Anbar HS; El-Gamal R; Tarazi H; Shehata MK; Abdel-Maksoud MS; Oh CH; El-Gamal MI
Eur J Med Chem; 2021 Nov; 224():113674. PubMed ID: 34237622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
